Publicaciones en colaboración con investigadores/as de Medical College of Wisconsin (6)

2024

  1. Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 33, pp. 2509-2520

2023

  1. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

2021

  1. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

    Leukemia, Vol. 34, Núm. 12, pp. 3298-3309

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

2003

  1. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group

    British Journal of Haematology, Vol. 121, Núm. 5, pp. 749-757